Sanofi to market Afrezza worldwide for Types 1 & 2 Diabetes - Sanofi/MannKind Corporation
Sanofi and MannKind Corporation have announced that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with Type 1 and Type 2 Diabetes. The companies plan to launch Afrezza in the United States in the first quarter of 2015 where the drug was approved on 27 June 2014.
Under the collaboration and license agreement, Sanofi will be responsible for global commercial, regulatory and development activities. Under a separate supply agreement, MannKind will manufacture Afrezza at its manufacturing facility in Danbury, Connecticut.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins